ArticleACS omega2024
Synergistic Effect in Hybrid Plasmonic Conjugates for Photothermal Applications.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Enhanced light harvesting through efficient energy transfer in a pluronic co-polymer scaffolded blend of donor dyes and plasmonic Au-MoSPhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Core-Shell Plasmonic Nanocomposites with Synergistic Photothermal and Photochemical Activity for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2026Review
- A review: advances of resveratrol co-delivery biomaterials-based system in anti-tumor therapy.Journal of materials science. Materials in medicine · 2025Review
- Nano-enabled strategies for targeted immunotherapy in gastrointestinal cancers.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photothermal conversion efficiency (η) plays a crucial role in selecting suitable gold nanoparticles for photothermal therapeutic applications. The photothermal efficiency depends on the material used for the nanoparticles as well as their various parameters, such as size and shape. By maximizing the light-to-heat conversion efficiency (η), one can reduce the concentration of nanoparticle drugs for photothermal cancer treatment and apply lower laser power to irradiate the tumor. In our study, we explored a new hybrid plasmonic conjugate for theranostic (therapy + diagnostic) applications. We conjugated PEG-functionalized 20 nm gold nanospheres with cyanine IR dyes via a PEG linker. The resulting conjugates exhibited significantly enhanced photothermal properties compared with bare nanoparticles. We experimentally showed that a proposed new hybrid plasmonic conjugate can achieve almost four times larger conversion efficiency (47.7%) than 20 nm gold nanospheres (12%). The enhanced photothermal properties of these gold conjugates can provide the required temperature for the photothermal treatment of cancer cells with lower concentrations of gold nanoparticles injected in the body as well as with lower applied incident laser power density. Moreover, the improved photothermal properties of the conjugates can be explained by a synergistic effect that has not been observed in the past. This effect results from the coupling between the metal nanosphere and the organic dye.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.